Manoussos Perros
Net Worth
Last updated:
What is Manoussos Perros net worth?
The estimated net worth of Dr. Manoussos Perros is at least $4,100,679 as of 19 Oct 2021. He owns shares worth $323,082 as insider, has earned $38,197 from insider trading and has received compensation worth at least $3,739,400 in Entasis Therapeutics Holdings Inc..
What is the salary of Manoussos Perros?
Dr. Manoussos Perros salary is $934,850 per year as Pres, Chief Executive Officer & Director in Entasis Therapeutics Holdings Inc..
How old is Manoussos Perros?
Dr. Manoussos Perros is 57 years old, born in 1968.
What stocks does Manoussos Perros currently own?
As insider, Dr. Manoussos Perros owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Entasis Therapeutics Holdings Inc. (ETTX) | Pres, Chief Executive Officer & Director | 147,526 | $2.19 | $323,082 |
What does Entasis Therapeutics Holdings Inc. do?
Entasis Therapeutics Holdings Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibacterial products to treat serious infections caused by multidrug-resistant pathogens in the United States. Its lead product candidate is sulbactam-durlobactam (SUL-DUR), a novel IV antibiotic that is in Phase III clinical trial for the treatment of pneumonia and bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii. The company also develops Zoliflodacin, a novel orally administered molecule, which is in Phase III clinical trial for the treatment of uncomplicated gonorrhea; ETX0282CPDP, an oral drug that is in Phase I clinical trial for the treatment of urinary tract infections; and ETX0462, a drug candidate from NBP platform that is in pre-clinical stage for the treatment of multidrug-resistant gram-negative infections. The company has a license and collaboration agreement with Zai Lab (Shanghai) Co., Ltd. for the development of durlobactam and SUL-DUR; and collaboration agreement with Global Antibiotic Research and Development Partnership for the development and commercialization of a product candidate zoliflodacin. Entasis Therapeutics Holdings Inc. was founded in 2015 and is headquartered in Waltham, Massachusetts. Entasis Therapeutics Holdings Inc. operates as a subsidiary of Innoviva, Inc.
Manoussos Perros insider trading
Entasis Therapeutics Holdings Inc.
Dr. Manoussos Perros has made only one insider trade in 2021, according to the Form 4 filled with the SEC. He sold 11,974 units of ETTX stock worth $38,197 on 19 Oct 2021.
As of 19 Oct 2021 he still owns at least 147,526 units of ETTX stock.
Entasis Therapeutics Holdings key executives
Entasis Therapeutics Holdings Inc. executives and other stock owners filed with the SEC:
- Dr. David Altarac (64) Chief Medical Officer
- Dr. John Patrick Mueller Ph.D. (65) Chief Devel. Officer
- Dr. Manoussos Perros (57) Pres, Chief Executive Officer & Director